WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317328
CAS#: 1235-82-1 (HCl)
Description: Biperiden hydrochloride is a muscarinic antagonist that has effects in both the central and peripheral nervous systems. Biperiden Hydrochloride has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Hodoodo Cat#: H317328
Name: Biperiden Hydrochloride
CAS#: 1235-82-1 (HCl)
Chemical Formula: C21H30ClNO
Exact Mass: 0.00
Molecular Weight: 347.920
Elemental Analysis: C, 72.49; H, 8.69; Cl, 10.19; N, 4.03; O, 4.60
Related CAS #: 1235-82-1 (HCl) 514-65-8 (free base) 7085-45-2 (lactate)
Synonym: Akineton; Akinophyl; Akineton hydrochloride; Biperiden; Biperiden Hydrochloride; Biperiden.
IUPAC/Chemical Name: 1-(5-Bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-(1-piperidinyl)propan-1-ol hydrochloride
InChi Key: RDNLAULGBSQZMP-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H29NO.ClH/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;1H
SMILES Code: C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. |
| In vitro activity: | Newly, this study described that biperiden (Bip) is a potent MALT1 inhibitor with even less pharmacological side effects. Thus, Bip is a promising drug leading to reduced proliferation and increased apoptosis in PDAC cells in vitro and in vivo. Reference: Int J Cancer. 2020 Mar 15;146(6):1618-1630. https://pubmed.ncbi.nlm.nih.gov/31291468/ |
| In vivo activity: | Biperiden at different doses (1.0, 5.0, and 10.0 mg/kg) blocked the expression of ethanol-induced CPP in mice. These biperiden doses increased the number of Fos-positive cells and the dopamine turnover in the nucleus accumbens. None of the doses affected the motor coordination evaluated by the rotarod. Reference: Neurosci Lett. 2021 Feb 6;745:135551. https://pubmed.ncbi.nlm.nih.gov/33346074/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 8.0 | 22.97 | |
| DMF | 0.5 | 1.44 | |
| Ethanol | 0.5 | 1.44 | |
| Water | 3.4 | 9.69 |
The following data is based on the product molecular weight 347.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Konczalla L, Perez DR, Wenzel N, Wolters-Eisfeld G, Klemp C, Lüddeke J, Wolski A, Landschulze D, Meier C, Buchholz A, Yao D, Hofmann BT, Graß JK, Spriestersbach SL, Grupp K, Schumacher U, Betzel C, Kapis S, Nuguid T, Steinberg P, Püschel K, Sauter G, Bockhorn M, Uzunoglu FG, Izbicki JR, Güngör C, El Gammal AT. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Int J Cancer. 2020 Mar 15;146(6):1618-1630. doi: 10.1002/ijc.32567. Epub 2019 Jul 25. PMID: 31291468. 2. Kostelnik A, Cegan A, Pohanka M. Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase. Biomed Res Int. 2017;2017:2532764. doi: 10.1155/2017/2532764. Epub 2017 Jul 13. PMID: 28785576; PMCID: PMC5530453. 3. Palombo P, Engi SA, Yokoyama TS, Bezerra AG, Curado DF, Anésio A, Leão RM, Santos PCJL, Cruz FC, Galduróz JCF. Effects of biperiden (cholinergic muscarinic m1/m4 receptor antagonist) on ethanol conditioned place preference in mice. Neurosci Lett. 2021 Feb 6;745:135551. doi: 10.1016/j.neulet.2020.135551. Epub 2020 Dec 17. PMID: 33346074. 4. Popelíková A, Bahník Š, Lobellová V, Svoboda J, Stuchlík A. Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat. Psychopharmacology (Berl). 2018 Jul;235(7):2013-2025. doi: 10.1007/s00213-018-4899-3. Epub 2018 Apr 21. PMID: 29680966. |
| In vitro protocol: | 1. Konczalla L, Perez DR, Wenzel N, Wolters-Eisfeld G, Klemp C, Lüddeke J, Wolski A, Landschulze D, Meier C, Buchholz A, Yao D, Hofmann BT, Graß JK, Spriestersbach SL, Grupp K, Schumacher U, Betzel C, Kapis S, Nuguid T, Steinberg P, Püschel K, Sauter G, Bockhorn M, Uzunoglu FG, Izbicki JR, Güngör C, El Gammal AT. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Int J Cancer. 2020 Mar 15;146(6):1618-1630. doi: 10.1002/ijc.32567. Epub 2019 Jul 25. PMID: 31291468. 2. Kostelnik A, Cegan A, Pohanka M. Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase. Biomed Res Int. 2017;2017:2532764. doi: 10.1155/2017/2532764. Epub 2017 Jul 13. PMID: 28785576; PMCID: PMC5530453. |
| In vivo protocol: | 1. Palombo P, Engi SA, Yokoyama TS, Bezerra AG, Curado DF, Anésio A, Leão RM, Santos PCJL, Cruz FC, Galduróz JCF. Effects of biperiden (cholinergic muscarinic m1/m4 receptor antagonist) on ethanol conditioned place preference in mice. Neurosci Lett. 2021 Feb 6;745:135551. doi: 10.1016/j.neulet.2020.135551. Epub 2020 Dec 17. PMID: 33346074. 2. Popelíková A, Bahník Š, Lobellová V, Svoboda J, Stuchlík A. Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat. Psychopharmacology (Berl). 2018 Jul;235(7):2013-2025. doi: 10.1007/s00213-018-4899-3. Epub 2018 Apr 21. PMID: 29680966. |
1: Kayipmaz AE, Giray TA, Tasci SS, Tasci SS, Kavalci C, Kocalar UG. Acute
dystonic reaction due to dexketoprofen trometamol. J Pak Med Assoc. 2015
Nov;65(11):1231-2. PubMed PMID: 26564300.
2: Affaticati A, Gerra ML, Amerio A, Inglese M, Antonioni MC, Marchesi C. The
Controversial Case of Biperiden: From Prescription Drug to Drug of Abuse. J Clin
Psychopharmacol. 2015 Dec;35(6):749-50. doi: 10.1097/JCP.0000000000000421. PubMed
PMID: 26479221.
3: Karadağ H, Acar M, Özdel K. Aripiprazole Induced Acute Transient Bilateral
Myopia: A Case Report. Balkan Med J. 2015 Apr;32(2):230-2. doi:
10.5152/balkanmedj.2015.15292. Epub 2015 Apr 1. PubMed PMID: 26167352; PubMed
Central PMCID: PMC4432708.
4: Danielmeier C, Allen EA, Jocham G, Onur OA, Eichele T, Ullsperger M.
Acetylcholine mediates behavioral and neural post-error control. Curr Biol. 2015
Jun 1;25(11):1461-8. doi: 10.1016/j.cub.2015.04.022. Epub 2015 May 7. PubMed
PMID: 25959965.
5: Ota T, Miura I, Kanno-Nozaki K, Hoshino H, Horikoshi S, Fujimori H, Kanno T,
Mashiko H, Yabe H. Effects of Shakuyaku-Kanzo-to on Extrapyramidal Symptoms
During Antipsychotic Treatment: A Randomized, Open-Label Study. J Clin
Psychopharmacol. 2015 Jun;35(3):304-7. doi: 10.1097/JCP.0000000000000312. PubMed
PMID: 25839338.
6: Stocker L, Jellestad L, Jenewein J, Boettger S. Challenges in the management
of delirium: a case of augmentation with donepezil following inadequate response
and adverse effects with risperidone. Psychiatr Danub. 2015 Mar;27(1):64-6.
PubMed PMID: 25751433.
7: Minár M, Valkovič P. Thyroid-induced worsening of parkinsonian tremor
resistant to drugs and subthalamic nucleus deep brain stimulation. Case Rep
Neurol Med. 2014;2014:489275. doi: 10.1155/2014/489275. Epub 2014 Dec 31. PubMed
PMID: 25628904; PubMed Central PMCID: PMC4297626.
8: Desmarais JE, Beauclair L, Annable L, Bélanger MC, Kolivakis TT, Margolese HC.
Effects of discontinuing anticholinergic treatment on movement disorders,
cognition and psychopathology in patients with schizophrenia. Ther Adv
Psychopharmacol. 2014 Dec;4(6):257-67. doi: 10.1177/2045125314553611. PubMed
PMID: 25489477; PubMed Central PMCID: PMC4257986.
9: Sambeth A, Riedel WJ, Klinkenberg I, Kähkönen S, Blokland A. Biperiden
selectively induces memory impairment in healthy volunteers: no interaction with
citalopram. Psychopharmacology (Berl). 2015 Jun;232(11):1887-97. doi:
10.1007/s00213-014-3822-9. Epub 2014 Dec 4. PubMed PMID: 25466702.
10: Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R,
Garbe E. Drug-induced liver injury: results from the hospital-based Berlin
Case-Control Surveillance Study. Br J Clin Pharmacol. 2015 Jun;79(6):988-99. doi:
10.1111/bcp.12565. PubMed PMID: 25444550; PubMed Central PMCID: PMC4456131.
11: Veselinović T, Vernaleken I, Janouschek H, Kellermann T, Paulzen M, Cumming
P, Gründer G. Effects of anticholinergic challenge on psychopathology and
cognition in drug-free patients with schizophrenia and healthy volunteers.
Psychopharmacology (Berl). 2015 May;232(9):1607-17. doi:
10.1007/s00213-014-3794-9. Epub 2014 Nov 7. PubMed PMID: 25373869.
12: Maltese M, Martella G, Madeo G, Fagiolo I, Tassone A, Ponterio G, Sciamanna
G, Burbaud P, Conn PJ, Bonsi P, Pisani A. Anticholinergic drugs rescue synaptic
plasticity in DYT1 dystonia: role of M1 muscarinic receptors. Mov Disord. 2014
Nov;29(13):1655-65. doi: 10.1002/mds.26009. Epub 2014 Sep 4. PubMed PMID:
25195914; PubMed Central PMCID: PMC4216601.
13: Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, Heinz BA,
Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Felder CC. M1 and m2
muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly
acting antidepressant scopolamine. J Pharmacol Exp Ther. 2014 Nov;351(2):448-56.
doi: 10.1124/jpet.114.216804. Epub 2014 Sep 3. PubMed PMID: 25187432.
14: Szczodry O, van der Staay FJ, Arndt SS. Modelling Alzheimer-like cognitive
deficits in rats using biperiden as putative cognition impairer. Behav Brain Res.
2014 Nov 1;274:307-11. doi: 10.1016/j.bbr.2014.08.036. Epub 2014 Aug 24. PubMed
PMID: 25160769.
15: Dieckmann LH, Ramos AC, Silva EA, Justo LP, Sabioni P, Frade IF, de Souza AL,
Galduróz JC. Effects of biperiden on the treatment of cocaine/crack addiction: a
randomised, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol.
2014 Aug;24(8):1196-202. doi: 10.1016/j.euroneuro.2014.06.001. Epub 2014 Jun 12.
PubMed PMID: 24974353.
16: Ghaffarlou M, Golzari SE, Nezami N. A large asymptomatic foreign body in
larynx and trachea. Quant Imaging Med Surg. 2014 Jun;4(3):210-1. doi:
10.3978/j.issn.2223-4292.2014.04.01. PubMed PMID: 24914423; PubMed Central PMCID:
PMC4032917.
17: Lertxundi U, Hernandez R, Albeniz JM, Echaburu SD, Ruiz B, García MG, Aguirre
C. Possible interaction between letrozole and long-acting injectable
zuclopenthixol. Nord J Psychiatry. 2015 Jan;69(1):79-80. doi:
10.3109/08039488.2014.915341. Epub 2014 May 16. PubMed PMID: 24831298.
18: Paraschakis A. Tackling negative symptoms of schizophrenia with memantine.
Case Rep Psychiatry. 2014;2014:384783. doi: 10.1155/2014/384783. Epub 2014 Apr
10. PubMed PMID: 24818033; PubMed Central PMCID: PMC4003755.
19: Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, Nemoto K, Kondo T. Effects
of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma
concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in
Japanese patients with schizophrenia. Ther Drug Monit. 2014 Oct;36(5):651-5. doi:
10.1097/FTD.0000000000000070. PubMed PMID: 24682161.
20: Ramachandran S, Osterhaus SR, Karp PH, Welsh MJ, McCray PB Jr. A genomic
signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance
regulator biosynthesis and function. Am J Respir Cell Mol Biol. 2014
Sep;51(3):354-62. doi: 10.1165/rcmb.2014-0007OC. PubMed PMID: 24669817; PubMed
Central PMCID: PMC4189493.
